Given the worldwide demand for vaccines to stop the spread of COVID-19, experts believe it will be important to move as many promising candidates forward as possible.
Explore This Research Lab
About the Lab
My research focuses on understanding the role of vasopressin receptor type 2 (V2R) signaling network in renal pathophysiology. V2R not only plays a key role in water and salt homeostasis so that defects in V2R signaling are associated with congenital or acquired nephrogenic diabetes insipidus and syndrome of inappropriate antidiuretic hormone secretion (SIADH), but V2R also plays a key role in hypertension and polycystic kidney diseases.
My lab uses cutting-edge molecular, pharmacological and biochemical techniques, and we use state-of-the-art microscopy to study protein trafficking and interactions. Using these techniques, we have showed that in contrary to common belief, the cAMP signal triggered by activation of V2R does not terminate at the membrane immediately. cAMP signal persists and continues into endosomes until terminated by internalized V2R. The physiological importance of endosomal cAMP signal is currently under investigation in our laboratory.
In addition, Dr. Dennis Brown and I are long-time collaborators on the study of the effect of V2R activation on cAMP-sensitive water channel aquaporin 2 (AQP2) trafficking. Our results highlight several alternative mechanisms that regulate AQP2 trafficking and play important roles in water reabsorption. Recently, we established the novel role of epidermal growth factor in water reabsorption. The importance of this cross-talk between EGFR and V2R in normal and polycystic kidneys is also under investigation.
- Press Release
- Jun | 9 | 2020
A drug already in use for several cancers was found effective in a study of leptomeningeal dissemination of cancer.
- Press Release
- Jun | 2 | 2020
A team led by investigators at Mass General and the Broad Institute of MIT and Harvard recently found that applying “polygenic risk scores” can identify at-risk patients who are not presently identified through standard clinical evaluations.
- Press Release
- May | 15 | 2020
A team led by researchers from Mass General has uncovered key molecular step stones in alcohol-related liver disease that may provide targets for drug therapy development.
- May | 12 | 2020
Neutralizando los anticuerpos específicos del SARS-CoV-2 y las células T específicas del virus detectadas en personas que se recuperan del COVID-19
El más reciente estudio sobre la inmunidad protectora en pacientes que se recuperan del COVID-19, publicado en Immunity, es el más completo hasta ahora. Sus prometedores resultados son discutidos por Tiara Calhoun, MD, y Vladimir Vinarsky, MD, con la asesoría de Rod Rahimi, MD, PhD.
- May | 1 | 2020
The National Institute of Allergy and Infectious Diseases (NIAID) reported April 29 that preliminary data from the study indicates that patients with advanced COVID-19 symptoms who received remdesivir recovered 31% faster than similar patients who received a placebo.
About the Nephrology Division
The Division of Nephrology at Massachusetts General Hospital is a leading provider of services for patients with kidney disease, including diagnosis and management of kidney diseases and medical management of renal transplantation.